Lord Prior of Brampton Alert Sample


Alert Sample

View the Parallel Parliament page for Lord Prior of Brampton

Information between 14th March 2022 - 8th December 2024

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.


Division Votes
11 Sep 2024 - Social Fund Winter Fuel Payment Regulations 2024 - View Vote Context
Lord Prior of Brampton voted Aye - in line with the party majority and in line with the House
One of 4 Non-affiliated Aye votes vs 1 Non-affiliated No votes
Tally: Ayes - 164 Noes - 132
4 Nov 2024 - Bank Resolution (Recapitalisation) Bill [HL] - View Vote Context
Lord Prior of Brampton voted Aye - in line with the party majority and in line with the House
One of 6 Non-affiliated Aye votes vs 4 Non-affiliated No votes
Tally: Ayes - 247 Noes - 125
4 Nov 2024 - Bank Resolution (Recapitalisation) Bill [HL] - View Vote Context
Lord Prior of Brampton voted Aye - against a party majority and against the House
One of 3 Non-affiliated Aye votes vs 6 Non-affiliated No votes
Tally: Ayes - 125 Noes - 155
5 Nov 2024 - Crown Estate Bill [HL] - View Vote Context
Lord Prior of Brampton voted Aye - in line with the party majority and in line with the House
One of 8 Non-affiliated Aye votes vs 2 Non-affiliated No votes
Tally: Ayes - 220 Noes - 139



Lord Prior of Brampton mentioned

Select Committee Documents
Tuesday 17th January 2023
Report - Twelfth Report - Documents considered by the Committee on 11 January 2023

European Scrutiny Committee

Found: for vehicles, as well as exchange of information (for example on safety 62 Letter from Lord Prior of Brampton

Wednesday 19th January 2022
Inquiry Publications - Tenth Report - Pre-appointment hearing for the position of Chair of NHS England

Health and Social Care Committee

Found: State for Health and Social Care wrote to inform us that the current Chair of NHS England, Lord Prior of Brampton



Written Answers
Antidepressants
Asked by: Lord Alton of Liverpool (Crossbench - Life peer)
Monday 5th February 2024

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord Prior of Brampton on 23 July 2015 (HL1632), how many prescriptions for antidepressants have been issued in each year since 2014; what was the annual cost to the National Health Service of those prescriptions; and what guidance is given to doctors and patients about the use of antidepressants, their subsequent withdrawal and potential long-term effects.

Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)

The following table shows the latest data available on the number of prescriptions for antidepressants issued between 2014 and 2023, and the associated net ingredient cost:

Time Period

Total Number of Items

Total Net Ingredient Cost (£)

2014

57,149,109

265,008,699

2015

61,021,662

284,746,655

2016

64,703,639

266,562,024

2017

67,530,457

235,076,090

2018

70,873,979

202,526,720

2019

74,814,621

201,729,659

2020

78,866,866

352,682,886

2021

82,620,542

288,099,250

2022

85,404,864

224,648,497

2023 (11 months)

80,970,256

211,852,277

The requirement to provide a patient information leaflet with licensed medicines in the United Kingdom is set out in Regulation 267 of the Human Medicines Regulations 2012. As set out in Schedule 27 of these regulations, the information that must be presented in the leaflet includes special warnings relevant to the safe use of the medicine, and instructions for proper use, including the risk of withdrawal effects and description of all side effects, both long and short term. The leaflet must reflect in lay language, the agreed Summary of Product Characteristics for a medicine, which would include information on risk of addiction, withdrawal and the long-term consequences of taking a medicine. The National Institute for Health and Care Excellence also set outs guidelines for the management and treatment of depression in adults.

Human Fertilisation and Embryology Authority
Asked by: Lord Alton of Liverpool (Crossbench - Life peer)
Thursday 29th June 2023

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord Prior of Brampton on 11 May 2016 (HL7950), and the Written Answer by Lord Markham on 6 June (HL7725), whether any research applications submitted to the Human Fertilisation and Embryology Authority (HFEA) since March 2011 have been rejected by the HFEA Licence Committee; whether any requests have been received by the HFEA to perform spindle-chromosomal complex transfer; and how many centres in the UK have been granted permission to perform pronuclear transfer in order to facilitate independent scientific validation.

Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)

The Human Fertilisation and Embryology Authority (HFEA) has advised that no research applications have been rejected by the HFEA Licence Committee since March 2011. No requests have been received by the HFEA to perform spindle-chromosomal complex transfer. One centre in the UK has been granted permission to perform pronuclear transfer which is the Newcastle Centre For Life.



Non-Departmental Publications - Transparency
May. 31 2022
Independent Adviser on Ministerial Standards
Source Page: List of ministers' interests
Document: List of ministers' interests - December 2016 (PDF)
Transparency

Found: Lord Prior of Brampton, Parliamentary Under Secretary of State !2.

May. 31 2022
Independent Adviser on Ministerial Standards
Source Page: List of ministers' interests
Document: List of ministers' interests - July 2016 (PDF)
Transparency

Found: Lord Prior of Brampton, Parliamentary Under Secretary of State !2.

May. 31 2022
Independent Adviser on Ministerial Standards
Source Page: List of ministers' interests
Document: List of ministers' interests - December 2015 (PDF)
Transparency

Found: Secretary of State See entry under the Department Business, Innovation and Skills Lord Prior of Brampton